Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NN-9931?
The revenue for NN-9931 is expected to reach an annual total of $18 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, …